Reappraisal of the safety data for biological DMARDs in treating inflammatory arthritis suggests that the benefits of use outweigh the risks

A narrative review has been published appraising the safety evidence regarding the use of biological DMARDs in treating inflammatory arthritis in pregnancy. The authors conclude that during pregnancy, the benefits of disease control with biological DMARDs, when required in addition to conventional synthetic DMARDs, outweigh the risks. More information is available here.

Photo by Anna Hecker on Unsplash